Group items tagged

Readers and consumers can better evaluate the versatility and multi-fold action of turmeric night cream given as follows: 1. Use It As An Eye Cream Combined with the potent antioxidant vitamin C, turmeric eye cream possesses beneficial properties that can combat dark circles under the eyes effectively. Turmeric's skin lightening and soothing traits can enhance circulation, thereby reducing under-eye puffiness and discoloration caused by inadequate blood flow. Further, its anti-inflammatory features, as well as its ability to lighten skin and increase microcirculation, make turmeric vitamin C eye cream an ideal ingredient in this case. 2. Turmeric Cream for Skin Whitening Turmeric is a sun-drenched tropical spice that has a wide range of skin-friendly benefits. It can help reduce oxidative stress and address skin conditions like dullness and dehydration. Turmeric cream can enhance the skin's radiance thanks to its healing, antioxidant, and anti-inflammatory properties that effectively cleanse and revitalize congested, inflamed, or impaired skin. Adding more turmeric to your skincare routine may enhance the skin's microcirculation, resulting in a firmer and more supple complexion. 3. Use Turmeric Cream For Hyperpigmentation Since turmeric inhibits the production of melanin, the utilization of vitamin C can effectively diminish hyperpigmentation. Hyperpigmentation is a skin problem in which some parts of the skin produce excessive melanin, resulting in blemishes such as sunspots, age spots, and melasma. It can possibly emerge in areas where the acne has been treated and healed previously. Turmeric can prevent the production of melanin responsible for dark spots and hyperpigmentation. Applying a product like a turmeric skin cream consistently can help reduce imperfections and provide a smoother, more even complexion.

The Medicines and Healthcare products Regulatory Agency (MHRA) has asked the pharmacies and wholesalers to stop supplying and quarantine all remaining stock of Dr Reddy's Laboratories (UK)'s Lacidipine 4 mg Film-Coated tablets. The company has recalled two batches of Lacidipine 4 mg Film-Coated tablets as a precautionary measure due to the presence of an unknown solvent-like odour. MHRA said: "The tablets are normally odourless. However, in the affected batches, a solvent-like odour is present when the individual blisters are opened. Additionally, some patient complaints have noted that the tablets have an unusual taste. The investigation to determine the root cause and to identify and quantify the odour is ongoing. "The issue is confined to batches B2202043 and B2202044 only. Other batches of Lacidipine 4 mg Film-Coated tablets marketed by Dr Reddy's Laboratories (UK) are not affected."

The drug, alpelisib, which is the 100th cancer drug that has being fast-tracked to patients under the NHS Cancer Drugs Fund (CDF) will be used in combination with the hormone therapy, fulvestrant, to target the gene that causes fast-growing tumours. Up to 3,000 people a year with a certain type of secondary breast cancer will benefit from the treatment. The approach has contributed to people in England having access to nearly one third more cancer drugs compared to the European average. The drug which is manufactured by pharmaceutical company Novartis, is part of a growing number of precision treatments that target a tumour based on mutations in its DNA and that the NHS is rolling out. John Stewart, NHS National Director for Specialised Commissioning said, "In just over five years, more than 80,000 people have benefitted from earlier access to a range of cancer drugs, with people in England having access to nearly one third more cancer drugs compared to the European average, and this latest innovative new treatment will help up to 3,000 more to live a better quality of life.

A report released by the Independent Commission has blamed Brexit supply issues for medicine shortages. NHS is forced to pay extortionate prices to fulfil the demand for vital antibiotics, anti-depressants, Attention Deficit Hyperactivity Disorder (ADHD), and Hormone Replacement Therapy (HRT) drugs. The report highlights the impact of affected medicine supply issues on community pharmacies and patients. Janet Morrison, the chief executive of Community Pharmacy England, backed the report and said that the "medicine shortages and market instability appear to be as bad as they have ever been". She also explained how the Ukraine conflict, the COVID-19 pandemic, and broader economic instability also play a major factor in the situation.

The Department of Health and Social Care (DHSC) on Thursday (30th November) announced the launch of a new suicide surveillance system, bolstering its efforts to tackle emerging methods of suicide and clamp down on those seeking to sell dangerous products to vulnerable people. For now, the DHSC will work with the National Police Chiefs' Council to gather near to real-time data from across the country on deaths by suspected suicide by gender, age group and method. The data will be obtained from individual police forces in England and the government will get it within three months of a suspected suicide, the DHSC said in its release. Previously, the only suicide data available at a national level was provided by the Office for National Statistics (ONS), but it could take up to 2 years for the official ONS data to come through.

Propofol is a versatile intravenous medication primarily known for its use in anesthesia to induce and maintain general anesthesia during surgeries and medical procedures. Its rapid onset of action and ability to provide smooth sedation have made it a popular choice in the medical field. However, beyond its well-established use in anesthesia, propofol has also shown promise in the field of depression treatment. It can be used as an antidote for depression.

Ventricular Septal Defect, a congenital heart condition characterized by a hole in the septum, the wall that separates the heart's lower chambers, poses a significant threat to cardiac health. Addressing VSD through surgery becomes imperative to restore normal cardiac function and prevent life-threatening consequences.

Members of the Pharmacists' Defence Association (PDA) who have benefits in the Boots Pension Scheme have sought support from their union following the recent communications from the trustees about the removal of the option to retire at 60 without a reduced pension. The company claimed that retirement between 60-65 years old without a reduced pension was a discretionary benefit, and it has ended with the buy-in deal with Legal and General. However, PDA members believe there is insufficient evidence to fully support this claim, and therefore they are questioning whether this option should have been secured as part of the buy in and not ended with immediate effect. PDA Union national officer, Paul Moloney said: "Instead, we believe benefit statements issued to members, at the very least are contradictory, and clearly state that a full pension will be payable from a member's 60th birthday, with no reference to this benefit being discretionary and therefore subject to a regular review by the trustees. Instead, the benefit statements give the impression that an unreduced pension from 60 is a right with no indication that retirement plans should not be based on the benefit statements."

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."

How Can I understand your desire to raise your iron levels quickly, it's crucial to prioritize safe and responsible methods that align with your individual health needs. Self-treating iron deficiency can be dangerous, so seeking professional guidance is vital. How Can I Raise My Iron Levels Fast? If dietary changes prove insufficient, your doctor might recommend iron supplements. However, dosage and type are crucial, and self-administration can be dangerous. Overconsumption can lead to iron overload, causing serious health problems.Remember, I am not a medical professional. This information is intended for general knowledge only and should not be used for self-diagnosis or treatment. Always consult a qualified healthcare provider for personalized guidance on raising your iron levels safely and effectively. Understanding Iron Deficiency: Iron deficiency occurs when your body lacks sufficient iron, impacting red blood cell production and oxygen delivery. It can trigger fatigue, weakness, and other symptoms. However, diagnosing the cause and severity is essential before taking action. Consult a healthcare professional for a proper diagnosis, blood tests, and personalized recommendations.

Adderall is a trading name for the combination drug that includes 4 types of amphetamine salts (Amphetamine aspartate, dextroamphetamine sulfate, dextroamphetamine saccharate, and amphetamine sulfate). In this, the two main ingredients Amphetamine and dextroamphetamine are the central nervous system stimulants that help to pay attention, stay focused, and control uncontrollable behavioral activities. Both Adderall vs Methylphenidate (commonly known as Ritalin) are stimulant medications prescribed for attention deficit hyperactivity disorder (ADHD). While they share the same goal of improving focus, attention, and reducing impulsivity, key differences exist in their composition, action, and side effects. Choosing the right one requires understanding these nuances and consulting a healthcare professional. Chemical Composition: Adderall: A brand name for a mixture of amphetamines (amphetamine and dextroamphetamine). These directly stimulate the central nervous system, increasing dopamine and norepinephrine levels. Methylphenidate: Not an amphetamine, but a psychostimulant that works by blocking the reuptake of dopamine and norepinephrine, essentially making them more available in the brain. Side Effects: Adderall: More likely to cause side effects like anxiety, insomnia, decreased appetite, headaches, and heart palpitations. Methylphenidate: More prone to causing side effects like nervousness, stomach upset, tics, and mood swings.

More than a third of pharmacists who participated in a survey said they have seen an increase in patients declining prescriptions due to the cost in the last 12 months. The survey was jointly conducted by the Pharmacists' Defence Association (PDA) and the Royal Pharmaceutical Society (RPS), extending their support for the Prescription Charges Coalition (PCC). Responding to the survey, 90 per cent of pharmacists admitted seeing cases where patients decline all the medicines on a prescription due to cost. Nearly all respondents said they have seen cases where patients declined some of their prescribed medicines and more than a quarter of them have experienced such situation often. They have warned of the impact of prescription charges as patients are denying vital medicines, including those for blood pressure and mental health, inhalers, antibiotics, pain relief, and statins, which can have potential consequences for the individual's health.

The UK has witnessed a nearly 50 percent increase in pharmacy closures this year compared to the same period in 2023, which was already considered the worst year in recent memory. A new analysis by the National Pharmacy Association (NPA) revealed that 177 pharmacies closed their doors between January and April 2024, compared to 116 in the same period last year. This is the equivalent of 10 local pharmacies shutting down every week. Analysis of NHS figures by the NPA showed that 403 pharmacies closed their doors last year, nearly five times higher than the number that closed in 2022. Since 2017, over 1,400 pharmacies have shut down across the UK. Rising costs and declining real terms funding have led to the fastest rate of closures in decades, said the NPA, highlighting that "real terms funding has decreased by 40 per cent over the last decade."

The Company Chemists' Association (CCA) has raised concern that pharmacies may face challenges in providing placements to pharmacy students graduating in 2025 due to shortages of designated prescribing practitioners (DPPs). From the academic year 2025/26, all pharmacy students will be required to complete 90 hours of training with designated prescribing practitioners prior to their registration. However, the CCA has raised doubts regarding the availability of these healthcare professionals to provide such training. The association said: "We are concerned that pharmacies will be unable to secure DPPs. This will result in a significant reduction in the number of Foundation Pharmacist placements available within the community pharmacy sector. Consequently, a significant number of graduates leaving university next year will, unfortunately, struggle to find employment in their chosen career." As per the CCA, they have repeatedly raised their concerns with NHS England and cautioned them about the potential consequences arising from the lack of DPPs.

The Government has been forced to intervene formally 50 times in the past two years to authorise the use of alternative drugs because of serious medicine shortages hitting patients, new analysis by the National Pharmacy Association (NPA) has found today. 78 per cent of all Serious Shortage Protocols, produced by the Department of Health and Social Care (DHSC) due to medicine shortages, were issued in 2022/24 - more than three times the rate in the previous two years. The NPA, which represents independent community pharmacies in the UK, is warning that shortages are leading to pharmacists having to increasingly turn patients needing vital medication away. Analysis by the NPA of the NHS's Serious Shortage Protocols (SSPs) issued to pharmacies and other providers over the last five years has found that: The number of SSPs issued in the last two years is 3.5 times higher than in the previous two years.

Expressing apprehension over the concerning decline in the nursing workforce, Sir Julian Hartley, CEO of NHS Providers, urged the forthcoming government to bolster investment in nursing education and enhance support for student nurses. Recent analysis from the Royal College of Nursing (RCN) has projected that the NHS Long Term Workforce Plan will fall short by 10,000 new nurses by 2025. Commenting on the RCN analysis, Sir Hartley underscored the critical importance of having an adequate number of nurses to ensure the delivery of safe, high-quality patient care. "Without enough nurses, the delivery of safe, high-quality patient care is compromised," he said. He cautioned that the predicted shortfall in nurses would exacerbate existing pressures on the NHS, resulting in long waiting times, delayed treatments and staff burnout.